合成目标产物 Cilastatin 主要起始原料 7-Chloro-2-[[[(1S)-2,2-Dimethylcyclopropyl]Carbonyl]Amino]-2-Heptenoic Acid And L-Cysteine Monohydrochloride
52-90-4 + 166037-21-4 = 82009-34-5 反应条件:1.1 Reagents: Sodium,Potassium Iodide Solvents: Methanol,Toluene1.2 - 标题:New Approach To The Synthesis Of Cilastatin,The Inhibitor Of Renal Dipeptidase 作者:Vinogradov,M. G.; Kaigorodova,L. N.; Chel'Tsova-Bebutova,G. V.; Gorshkova,L. S.; Starostin,E. K.; Et Al 参考文献:Izvestiya Akademii Nauk 日期:1995 卷标:(1) 页码:171-5]
52-90-4 + 78834-80-7 = 82009-34-5 反应条件:1.1 Reagents: Sodium Solvents: Methanol,Ammonia 标题:Inhibition Of The Mammalian β-Lactamase Renal Dipeptidase (Dehydropeptidase-I) By Z-2-(Acylamino)-3-Substituted-Propenoic Acids 作者:Graham,Donald W.; Ashton,Wallace T.; Barash,Louis; Brown,Jeannette E.; Brown,Ronald D.; Et Al 参考文献:Journal Of Medicinal Chemistry 日期:1987 卷标:30(6) 页码:1074-90
7-Bromo-2-Oxoheptanoic Acid置于氨,Sodium体系中,用 甲苯 作为反应溶剂,化学反应 0.25H,反应生成 西司他丁 参考文献:Inhibition Of The Mammalian .Beta.-Lactamase Renal Dipeptidase (Dehydropeptidase-I) By Z-2-(Acylamino)-3-Substituted-Propenoic Acids 标题:Inhibition Of The Mammalian .Beta.-Lactamase Renal Dipeptidase (Dehydropeptidase-I) By Z-2-(Acylamino)-3-Substituted-Propenoic Acids 摘要:The Title Enzyme Deactivates The Potent Carbapenem Antibiotic Imipenem In The Kidney,Producing Low Antibiotic Levels In The Urinary Tract. A Series Of (Z)-2-(Acylamino)-3-Substituted-Propenoic Acids (3) Are Specific,Competitive Inhibitors Of The Enzyme Capable Of Increasing The Urinary Concentration Of Imipenem In Vivo. Many Of The Compounds Were Prepared In One Step From An Alpha-Keto Acid And A Primary Amide. The Optimum R2 Groups Are 2,2-Dimethyl,-Dichloro,And-Dibromocyclopropyl. With R2 = 2,2-Dimethylcyclopropyl (Dmcp),A Wide Variety Of R3 Groups Including Alkyl,Oxa-And Thiaalkyl,And Alkyl Groups Containing Acidic,Basic,And Neutral Substituents Give Effective Inhibitors With Ki Values Of 0.02-1 Microm And A Range Of Pharmacokinetic Properties. By Resolution Of Enantiomers And X-Ray Crystallography,The Enzyme-Inhibitory Activity Of The Dmcp Group Was Found To Reside With The 1S Isomer. The Cysteinyl Compound 176 (Cilastatin,Mk-0791) Has The Desired Pharmacological Properties And Has Been Chosen For Combination With Imipenem. DOI:10.1021/jm00389A018
专利号:US-2024197774-A1 优先权日:2021-04-16 标 题:Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles 发明人:LOPEZ-RIBOT JOSE; VAZQUEZ-MUNOZ ROBERTO 权利人:UNIV TEXAS 摘要:Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.
专利号:US-2023286915-A1 优先权日:2020-10-07 标 题 :Synthesis of pyrrole acid derivatives 发明人:WILKINSON ANDREW; COOPER LAN; ORR DAVID; FINLAYSON JONATHAN; BUNT ADAM; KIRKHAM JAMES; LYTH DAVID; BLADES KEVIN 权利人:INFEX THERAPEUTICS LTD 摘要:This invention relates to the synthesis of compounds that can be used to treat bacterial infections in combination with other antibacterial agents, and more specifically in combination with a class of antibacterial agents known as carbapenems. The compounds resulting from the novel methods of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.
专利号:US-11744867-B2 优先权日:2017-02-14 标 题 :Modulation of microbial synthesis of 4-ethylphenol and 4-ethylphenyl sulfate in behavior and disease 发明人:NEEDHAM BRITTANY D; MAZMANIAN SARKIS K; SHARON GIL; FUNABASHI MASANORI; FISCHBACH MICHAEL A; HSIAO ELAINE Y; PATTERSON PAUL H 权利人:CALIFORNIA INST OF TECHN; UNIV CALIFORNIA 摘要:Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.
专利号:US-8557979-B2 优先权日:2004-06-10 标题 :Carbapenem antibacterials with gram-negative activity and processes for their preparation 发明人:CHOI WOO-BAEG; KOWALIK EWA 权利人:CHOI WOO-BAEG; KOWALIK EWA; FOB SYNTHESIS INC 摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of β-methyl carbapenems which are useful as antibacterial agents.
专利号:US-2022233673-A1 优先权日:2019-06-04 标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF 发明人:BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M 权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND 摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.
专利号:US-10933051-B2 优先权日:2017-06-09 标 题 :Carbapenem compounds and compositions for the treatment of bacterial infections 发明人:CHOI WOO-BAEG; TOMIOKA TAKASHI; JOO HYUNG-YEUL; TRUONG PHONG; MIN BRIAN 权利人:FOB SYNTHESIS INC 摘要:The present invention provides carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections, including drug resistant or multiple-drug resistant bacterial infections, and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
1: Davani F, Alishahi M, Sabzi M, Khorram M, Arastehfar A, Zomorodian K. Dual drug delivery of vancomycin and imipenem/cilastatin by coaxial nanofibers for treatment of diabetic foot ulcer infections. Mater Sci Eng C Mater Biol Appl. 2021 Apr;123:111975. doi: 10.1016/j.msec.2021.111975. Epub 2021 Feb 15. 81(3):377-388. doi: 10.1007/s40265-021-01471-8. Epub 2021 Feb 25. 3: Yamada K, Jahangiri Y, Li J, Gabr A, Anoushiravani A, Kumagai K, Uchida B, Farsad K, Horikawa M. Embolic Characteristics of Imipenem-Cilastatin Particles in Vitro and in Vivo: Implications for Transarterial Embolization in Joint Arthropathies. J Vasc Interv Radiol. 2021 Feb 16:S1051-0443(21)00336-5. doi: 10.1016/j.jvir.2021.02.006. Epub ahead of print. 78(8):674-683. doi: 10.1093/ajhp/zxab012. 65(4):e02141-20. doi: 10.1128/AAC.02141-20. 22(3):1239. doi: 10.3390/ijms22031239.
合成参考文献
参考文献:10.1186/cc8877 摘要:Augustin P, Kermarrec N, Muller-Serieys C, Lasocki S, Chosidow D, Marmuse JP, Valin N, Desmonts JM, Montravers P. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care. 2010;14(1):R20. 参考文献:10.1186/1756-0500-4-236 摘要:Marinho DS, Huf G, Ferreira BL, Castro H, Rodrigues CR, de Sousa VP, Cabral LM. The study of vancomycin use and its adverse reactions associated to patients of a Brazilian university hospital. BMC Res Notes. 2011 Jul 15;4():236.